As the 28th European congress on Obesity draws near, Prof Cusi, USA explains a paradigm shift and why drugs that have had an impact for CV disease also have a significant potential in the management of NASH. Amongst them, PPARs may have a role to play in addition to management of obesity and lifestyle interventions.

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In

two × three =